At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Linsitinib, and 2 other interventions for Recurrent Small Cell Lung Carcinoma. Completed, enrolled 44 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of participants with relapsed or recurrent Small Cell Lung Cancer. This study also plans to find out what effects, good or bad (side effects), OSI-906 has on participants and or Small Cell Lung Cancer. The study will also investigate if some proteins measured in the blood or tumor and some imaging features obtained from computed tomography (CT) scans can help predict whether OSI-906 or topotecan will be effective against Small Cell Lung Cancer.
Study Details
Timeline
Interventions
Correlative studies
150 mg given orally (PO) twice a day (BID)
Correlative studies
1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)